RedHill Biopharma (RDHL) Free Cash Flow (2016 - 2022)
Historic Free Cash Flow for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to -$2.4 million.
- RedHill Biopharma's Free Cash Flow rose 8370.36% to -$2.4 million in Q4 2022 from the same period last year, while for Dec 2023 it was -$2.4 million, marking a year-over-year increase of 9164.8%. This contributed to the annual value of -$9.4 million for FY2024, which is 7386.13% up from last year.
- RedHill Biopharma's Free Cash Flow amounted to -$2.4 million in Q4 2022, which was up 8370.36% from -$6.0 million recorded in Q3 2022.
- RedHill Biopharma's Free Cash Flow's 5-year high stood at -$2.4 million during Q4 2022, with a 5-year trough of -$19.0 million in Q3 2021.
- Its 5-year average for Free Cash Flow is -$10.8 million, with a median of -$9.9 million in 2018.
- Per our database at Business Quant, RedHill Biopharma's Free Cash Flow crashed by 11103.83% in 2021 and then skyrocketed by 8370.36% in 2022.
- Quarter analysis of 5 years shows RedHill Biopharma's Free Cash Flow stood at -$8.2 million in 2018, then crashed by 68.96% to -$13.8 million in 2019, then rose by 8.53% to -$12.7 million in 2020, then dropped by 17.38% to -$14.9 million in 2021, then surged by 83.7% to -$2.4 million in 2022.
- Its Free Cash Flow was -$2.4 million in Q4 2022, compared to -$6.0 million in Q3 2022 and -$16.4 million in Q2 2022.